

# Daniel E Speiser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8153591/publications.pdf>

Version: 2024-02-01

145  
papers

15,783  
citations

32410

55  
h-index

21843

118  
g-index

155  
all docs

155  
docs citations

155  
times ranked

24727  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149.	2.7	26
2	A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 243-257.	2.7	35
3	Sensitive identification of neoantigens and cognate TCRs in human solid tumors. <i>Nature Biotechnology</i> , 2022, 40, 656-660.	9.4	41
4	Shared acute phase traits in effector and memory human CD8 T cells. <i>Current Research in Immunology</i> , 2022, 3, 1-12.	1.2	2
5	Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927.		14
6	The Future of SARS-CoV-2 Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 899-900.	13.9	4
7	Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron. <i>Vaccines</i> , 2022, 10, 743.	2.1	11
8	Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism. <i>Npj Vaccines</i> , 2022, 7, .	2.9	6
9	SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. <i>Npj Vaccines</i> , 2021, 6, 2.	2.9	48
10	Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. <i>Cell Reports Medicine</i> , 2021, 2, 100194.	3.3	77
11	Not All Tumor-Infiltrating CD8+ T Cells Are Created Equal. <i>Cancer Cell</i> , 2021, 39, 145-147.	7.7	5
12	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. <i>Science Advances</i> , 2021, 7, .	4.7	157
13	Constant regulation for stable CD8 T cell functional avidity and its possible implications for cancer immunotherapy. <i>European Journal of Immunology</i> , 2021, 51, 1348-1360.	1.6	4
14	Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma. <i>Oncotarget</i> , 2021, 12, 638-648.	0.8	2
15	Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2471-2481.	1.4	8
16	Melanoma dedifferentiation induced by IFN- $\beta$ epigenetic remodeling in response to anti-PD-1 therapy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
17	Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients. <i>Oncimmunology</i> , 2021, 10, 1873585.	2.1	15
18	Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. <i>Oncimmunology</i> , 2021, 10, 2006893.	2.1	4

#	ARTICLE	IF	CITATIONS
19	Virus-like particles for vaccination against cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1579.	3.3	74
20	High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence. <i>Frontiers in Immunology</i> , 2020, 10, 3016.	2.2	11
21	Murine CD8 T cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density. <i>European Journal of Immunology</i> , 2020, 50, 505-514.	1.6	6
22	Analysis of cancer cell-intrinsic immune regulation in response to CD8 + T cell attack. <i>Methods in Enzymology</i> , 2020, 631, 443-466.	0.4	0
23	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	77
24	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. <i>Cancer Immunology Research</i> , 2020, 8, 1180-1192.	1.6	19
25	The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin. <i>Nature Immunology</i> , 2020, 21, 1034-1045.	7.0	90
26	BAFF 60-mer, and Differential BAFF 60-mer Dissociating Activities in Human Serum, Cord Blood and Cerebrospinal Fluid. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 577662.	1.8	10
27	COVID-19: Mechanisms of Vaccination and Immunity. <i>Vaccines</i> , 2020, 8, 404.	2.1	81
28	Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. <i>Immunity</i> , 2020, 53, 985-1000.e11.	6.6	107
29	Conserved Interferon- $\gamma$ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	7.7	203
30	LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures. <i>Oncotarget</i> , 2020, 9, 1736792.	2.1	36
31	Identification of a superagonist variant of the immunodominant Yellow fever virus epitope NS4b 214-222 by combinatorial peptide library screening. <i>Molecular Immunology</i> , 2020, 125, 43-50.	1.0	0
32	Immunosuppressive Mediators Impair Proinflammatory Innate Lymphoid Cell Function in Human Malignant Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 556-564.	1.6	21
33	Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies. <i>Vaccine</i> , 2020, 38, 2172-2182.	1.7	10
34	Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. <i>International Journal of Molecular Sciences</i> , 2020, 21, 636.	1.8	15
35	Early drop of circulating T cells negatively correlates with the protective immune response to Yellow Fever vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3103-3110.	1.4	3
36	Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients. , 2020, 8, e000435.		4

#	ARTICLE	IF	CITATIONS
37	Cover Image, Volume 12, Issue 1. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1610.	3.3	0
38	Attenuation of chronic antiviral T-cell responses through constitutive COX2-dependent prostanoid synthesis by lymph node fibroblasts. PLoS Biology, 2019, 17, e3000072.	2.6	18
39	Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma. Frontiers in Immunology, 2019, 10, 2115.	2.2	2
40	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
41	Intratumoral CD8 <sup>+</sup> T cells with stem cell-like properties: Implications for cancer immunotherapy. Science Translational Medicine, 2019, 11, .	5.8	42
42	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
43	Defining T cell exhaustion™. Nature Reviews Immunology, 2019, 19, 665-674.	10.6	879
44	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nature Immunology, 2019, 20, 206-217.	7.0	51
45	Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Experimental Gerontology, 2019, 124, 110633.	1.2	11
46	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. Frontiers in Immunology, 2019, 10, 1015.	2.2	39
47	High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. Clinical Cancer Research, 2019, 25, 4320-4331.	3.2	15
48	Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1043.	3.4	266
49	Maf deficiency in T cells dysregulates Treg - TH17 balance leading to spontaneous colitis. Scientific Reports, 2019, 9, 6135.	1.6	25
50	MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. Cancer Immunology Research, 2019, 7, 1013-1024.	1.6	24
51	Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.		41
52	Circulating CD56bright NK cells inversely correlate with survival of melanoma patients. Scientific Reports, 2019, 9, 4487.	1.6	63
53	Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. Journal of Experimental Medicine, 2019, 216, 1091-1107.	4.2	102
54	Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. Journal of Clinical Medicine, 2019, 8, 2089.	1.0	20

#	ARTICLE	IF	CITATIONS
55	Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. <i>Immunity</i> , 2019, 50, 195-211.e10.	6.6	924
56	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	229
57	The C-terminal extension landscape of naturally presented HLA-I ligands. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 5083-5088.	3.3	48
58	T cell receptor alpha variable 12 bias in the immunodominant response to Yellow fever virus. <i>European Journal of Immunology</i> , 2018, 48, 258-272.	1.6	44
59	Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 39-45.	2.0	45
60	Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness. <i>PLoS Biology</i> , 2018, 16, e2005523.	2.6	46
61	Lymphatic vessel density is associated with CD8 <sup>+</sup> T cell infiltration and immunosuppressive factors in human melanoma. <i>Oncolmmunology</i> , 2018, 7, e1462878.	2.1	47
62	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 4912-4923.	3.9	214
63	Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells. <i>Cancer Research</i> , 2017, 77, 1623-1636.	0.4	13
64	T memory stem cells in health and disease. <i>Nature Medicine</i> , 2017, 23, 18-27.	15.2	396
65	More T Cells versus Better T Cells in Patients with Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1062-1064.	7.7	6
66	Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	174
67	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. <i>European Urology</i> , 2017, 71, 854-857.	0.9	22
68	Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3285-3296.	3.2	47
69	Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. <i>ELife</i> , 2017, 6, .	2.8	795
70	TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency. <i>JCI Insight</i> , 2017, 2, .	2.3	46
71	ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2916-2929.	3.9	176
72	A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. <i>Frontiers in Immunology</i> , 2016, 7, 326.	2.2	22

#	ARTICLE	IF	CITATIONS
73	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. <i>Frontiers in Immunology</i> , 2016, 7, 573.	2.2	73
74	Regulatory circuits of T cell function in cancer. <i>Nature Reviews Immunology</i> , 2016, 16, 599-611.	10.6	445
75	Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. <i>Oncolmunology</i> , 2016, 5, e1231292.	2.1	89
76	Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. <i>American Journal of Human Genetics</i> , 2016, 99, 1190-1198.	2.6	135
77	Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies. <i>Cancer Discovery</i> , 2016, 6, 17-19.	7.7	8
78	Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial. <i>Clinical Cancer Research</i> , 2016, 22, 1330-1340.	3.2	74
79	From T cell “exhaustion” to anti-cancer immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 49-57.	3.3	18
80	Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. <i>EMBO Journal</i> , 2015, 34, 2042-2058.	3.5	100
81	Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans. <i>Genomics Data</i> , 2015, 5, 297-301.	1.3	11
82	Inhibitory Receptors Beyond T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2015, 6, 310.	2.2	188
83	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	2.2	73
84	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>Oncolmunology</i> , 2015, 4, e998538.	2.1	119
85	Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence. <i>Journal of Immunology</i> , 2015, 195, 356-366.	0.4	30
86	Identification of Rare High-Avidity, Tumor-Reactive CD8 <sup>+</sup> T Cells by Monomeric TCR Ligand Off-Rates Measurements on Living Cells. <i>Cancer Research</i> , 2015, 75, 1983-1991.	0.4	54
87	Long-lasting stem cell-like memory CD8 <sup>+</sup> T cells with a naïve-like profile upon yellow fever vaccination. <i>Science Translational Medicine</i> , 2015, 7, 282ra48.	5.8	174
88	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Oncolmunology</i> , 2015, 4, e1029702.	2.1	17
89	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15408-15413.	3.3	404
90	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395

#	ARTICLE	IF	CITATIONS
91	Cancer immunotherapy drives implementation science in oncology. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3107-3110.	1.4	8
92	Pulmonary Sarcoid-like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 1148-1153.	1.6	8
93	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 <sup>+</sup> T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128.	5.8	325
94	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <i>Nature Reviews Immunology</i> , 2014, 14, 768-774.	10.6	248
95	Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer. <i>PLoS ONE</i> , 2014, 9, e93321.	1.1	19
96	T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. <i>Nature Immunology</i> , 2013, 14, 603-610.	7.0	228
97	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <i>Expert Review of Vaccines</i> , 2013, 12, 1325-1340.	2.0	5
98	Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. <i>Clinical Cancer Research</i> , 2013, 19, 5749-5757.	3.2	113
99	Hit Parade for Adoptive Cell Transfer Therapy: The Best T Cells for Superior Clinical Responses. <i>Cancer Discovery</i> , 2013, 3, 379-381.	7.7	4
100	Molecular Insights for Optimizing T Cell Receptor Specificity Against Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 154.	2.2	35
101	Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 <sup>+</sup> T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 455.	2.2	202
102	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	9
103	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. <i>Journal of Clinical Investigation</i> , 2013, 123, 1044-1056.	3.9	109
104	Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e78686.	1.1	15
105	A molecular profile of T-cell exhaustion in cancer. <i>Onc Immunology</i> , 2012, 1, 369-371.	2.1	6
106	Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8 <sup>+</sup> T Cell Responsiveness. <i>Journal of Biological Chemistry</i> , 2012, 287, 23068-23078.	1.6	121
107	The three main stumbling blocks for anticancer T cells. <i>Trends in Immunology</i> , 2012, 33, 364-372.	2.9	127
108	Nano-particle vaccination combined with TLR7 and 9 ligands triggers memory and effector CD8 <sup>+</sup> T cell responses in melanoma patients. <i>European Journal of Immunology</i> , 2012, 42, 3049-3061.	1.6	173

#	ARTICLE	IF	CITATIONS
109	Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. <i>Nature Genetics</i> , 2012, 44, 133-139.	9.4	369
110	Vaccination-induced functional competence of circulating human tumor-specific CD8 T cells. <i>International Journal of Cancer</i> , 2012, 130, 2607-2617.	2.3	56
111	Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. <i>Journal of Translational Medicine</i> , 2011, 9, 44.	1.8	67
112	Reversible Major Histocompatibility Complex I-Peptide Multimers Containing Ni <sup>2+</sup> -Nitrilotriacetic Acid Peptides and Histidine Tags Improve Analysis and Sorting of CD8+ T Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 41723-41735.	1.6	42
113	Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. <i>Journal of Clinical Investigation</i> , 2011, 121, 2350-2360.	3.9	707
114	Frequent MAGE Mutations in Human Melanoma. <i>PLoS ONE</i> , 2010, 5, e12773.	1.1	22
115	Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function. <i>Journal of Immunology</i> , 2010, 184, 4936-4946.	0.4	196
116	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. <i>Seminars in Immunology</i> , 2010, 22, 144-154.	2.7	39
117	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. <i>Journal of Clinical Investigation</i> , 2010, 120, 157-167.	3.9	252
118	Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts. <i>Cancer Research</i> , 2009, 69, 8085-8093.	0.4	40
119	Dominant Human CD8 T Cell Clonotypes Persist Simultaneously as Memory and Effector Cells in Memory Phase. <i>Journal of Immunology</i> , 2009, 182, 6718-6726.	0.4	18
120	Fine Structural Variations of $\hat{\pm}\hat{2}$ TCRs Selected by Vaccination with Natural versus Altered Self-Antigen in Melanoma Patients. <i>Journal of Immunology</i> , 2009, 183, 5397-5406.	0.4	48
121	Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3849-3854.	3.3	136
122	Distinct sets of $\hat{\pm}\hat{2}$ TCRs confer similar recognition of tumor antigen NY-ESO-1 <sub>157-165</sub> by interacting with its central Met/Trp residues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15010-15015.	3.3	39
123	In Vivo Persistence of Codominant Human CD8+T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. <i>Journal of Immunology</i> , 2007, 179, 2368-2379.	0.4	26
124	Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. <i>European Journal of Immunology</i> , 2006, 36, 1805-1814.	1.6	17
125	A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination. <i>Journal of Immunology</i> , 2006, 177, 1338-1348.	0.4	78
126	Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers. <i>Journal of Immunology</i> , 2006, 177, 6769-6779.	0.4	48



#	ARTICLE	IF	CITATIONS
127	New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site. <i>Journal of Immunology</i> , 2006, 177, 1670-1678.	0.4	157
128	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>Journal of Clinical Investigation</i> , 2005, 115, 739-746.	3.9	569
129	Toward improved immunocompetence of adoptively transferred CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1467-1469.	3.9	28
130	Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. <i>Cancer Research</i> , 2004, 64, 2865-2873.	0.4	351
131	Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon- $\gamma$ ELISPOT Assays for Patient Immune Monitoring. <i>Journal of Immunotherapy</i> , 2004, 27, 298-308.	1.2	40
132	Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. <i>Seminars in Cancer Biology</i> , 2003, 13, 461-472.	4.3	50
133	Disease-driven T cell activation predicts immune responses to vaccination against melanoma. <i>Cancer Immunity</i> , 2003, 3, 12.	3.2	8
134	In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. <i>European Journal of Immunology</i> , 2002, 32, 731.	1.6	96
135	Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. <i>Cancer Immunity</i> , 2002, 2, 14.	3.2	10
136	Human CD8+ T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. <i>European Journal of Immunology</i> , 2001, 31, 459-466.	1.6	48
137	TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion after virus infection but contribute to peptide-induced deletion under limited conditions. <i>European Journal of Immunology</i> , 2000, 30, 683-688.	1.6	72
138	Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma. <i>Journal of Immunology</i> , 2000, 165, 7253-7261.	0.4	77
139	In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma-Specific Cytolytic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1999, 190, 775-782.	4.2	179
140	Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. <i>International Immunology</i> , 1999, 11, 1971-1980.	1.8	49
141	High Frequencies of Naive Melan-a/Mart-1-Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals. <i>Journal of Experimental Medicine</i> , 1999, 190, 705-716.	4.2	447
142	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. <i>European Journal of Immunology</i> , 1999, 29, 1990-1999.	1.6	111
143	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. , 1999, 29, 1990.		1
144	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. , 1999, 29, 1990.		7

#	ARTICLE	IF	CITATIONS
145	Extrathymic positive selection of $\hat{I}\pm\hat{I}^2$ T-cell precursors in nude mice. Nature, 1992, 355, 170-172.	13.7	39